



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/038,894	03/11/1998	ROLAND STOUGHTON	17124-003001 / 2202	8909
20985	7590	11/04/2008	EXAMINER	
FISH & RICHARDSON, PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022				MELLER, MICHAEL V
ART UNIT		PAPER NUMBER		
1655				
NOTIFICATION DATE			DELIVERY MODE	
11/04/2008			ELECTRONIC	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/038,894	STOUGHTON ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Michael V. Meller	1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 30 July 2008.
- 2a) This action is **FINAL**.                  2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 10-18,32-36,38,41 and 42 is/are pending in the application.
- 4a) Of the above claim(s) 17,33 and 38 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 10-16,18,32,34-36,41 and 42 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ .  | 6) <input type="checkbox"/> Other: _____ .                        |

## DETAILED ACTION

### *Election/Restrictions*

The election of species of record is maintained for the reasons of record.

Applicant elected trauma as the disease/condition, futhan (nafamostate mesilate) as the activation lowering therapy and free radical production as the cell activation assessment method.

Applicant argues that claims 17, 33 and 38 should not be withdrawn from consideration but it is clear that these claims were subjected to an election of species requirement as noted above. Since applicant elected trauma as the disease/condition, futhan (nafamostate mesilate) as the activation lowering therapy and free radical production as the cell activation assessment method, claims 17, 33 and 38 are withdrawn since they claim non-elected subject matter since the disease/condition elected was trauma which is not in claim 17 and since futhan was elected as the activation lowering therapy then claims 33 and 38 are withdrawn from consideration since they do not include futhan.

Thus, claims 17, 33, 38 remain withdrawn from further consideration by the examiner as being drawn to non-elected subject matter. This requirement has already been made FINAL.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 10-16, 18, 32, 34-36, 41, 42 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims do not have written description from the specification since the specification states that the invention (on page 19, lines 10-17 of the instant specification) may cure a disease. There is no way whatsoever that applicant had possession at the time the invention was made to a cure for any and all diseases. How

can applicant possibly have had possession at the time the invention was made to cure any and all diseases ? The fact is there is no evidence, data anything that supports that the claimed invention can cure any and all diseases. In fact, there is nothing of record to show that the invention can cure any disease. The claims read on curing AIDS, cancer, etc. Since there is no way whatsoever that applicant has found how to cure these incurable diseases, it is clear that there is no way whatsoever that applicant could have had possession of the claimed invention at the time the invention was made.

Applicant argues that the claims do not purport to cure a disease but rather to offer a method of treatment, but as seen on page 19, lines 10-17 of the instant specification the “effective amount” of the compound is defined as a possible cure of a disease. The “effective amount” of the compound is also said to ameliorate the disease, but it is offered as a possible cure to a disease as well.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

Art Unit: 1655

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 10, 12, 13, and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Adams et al.

As the Board of Appeals noted in their decision of May 18, 2006, claim 32 reads on bed rest. The Board stated that the claim reads on a subject recognizing that the subject is experiencing inflammation. The Board stated also that it would seem to them quite clear that inflammation results from the release of inflammatory mediators. Therefore, administering an anti-inflammatory to the subject would prevent a disease or disorder that is within the scope of applicant's claimed invention. The Board stated that

Art Unit: 1655

according to Adams (column 1, lines 1-20), “[a]n early event in the response of most inflammatory cells to immunologic activation and other stimuli is the release of newly formed products (mediators) which alter the function and biochemistry of surrounding cells and tissues.” Therefore, all subjects experiencing inflammation will have elevated levels of inflammatory mediators. Adams proposes to treat this condition by administering a compound of Formula (I). See abstract, and column 4, line 50-column 5, line 17. Note that the claims are met since assessment was done and activation levels were increased (since inflammation was experienced) and that activation lowering therapy was administered before treatment for the disease since the protease inhibitor is the treatment.

It is noted that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other “procedure” be used to assess cell activation. Accordingly (the Board concluded in their decision) that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the Board's decision.

A close examination of Adams reveals that Adams is treating inflammation. The Board considered Adams to be on point with the claimed invention, thus Adams is applied herein for the reasons cited by the Board.

Adams is treating trauma since as noted by Groutas, inflammation is associated with tissue trauma, see Groutas, column 1, lines 10-20.

Applicant argues here that Adams does not measure the level of activation of white blood cells, but as noted by the Cleveland Clinic (see enclosed reference)

Art Unit: 1655

inflammation is a process by which the body's white blood cells and chemicals protect us from infection and forging substances such as bacteria and viruses, thus it is inherent that white blood cells were assessed and activation levels were increased in Adams (since inflammation was experienced) and that activation lowering therapy was administered before treatment for the disease since the protease inhibitor is the treatment.

Note as before that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other "procedure" be used to assess cell activation. Accordingly (the Board concluded in their decision) that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the Board's decision. Applicant states that the board is in error on this fact but the arguments are not persuasive. The board made it clear that the "assessment" or "measurement" that applicant is referring to is simply the subject recognizing that it is experiencing inflammation thus needing activation lowering therapy. Thus, determining whether the level of activation of white blood cells is elevated or not is clear since it was elevated since the treatment was administered in the reference. Since the subject has experienced the inflammation the subject will take the drug to treat the inflammation.

Applicant has noted the same arguments as noted before, thus the rebuttal is the same as of record.

Claims 10, 12-16, 32, and 34-36 are rejected under 35 U.S.C. 102(b) as being anticipated by Groutas.

Groutas teaches that inflammation is associated with tissue trauma. Groutas also teaches that alpha-1-proteinase inhibitor is administered to reduce inflammation (see column 1, lines 1-45). Thus, as with the teachings of Adams as noted by the Board, the administration of alpha-1-proteinase will also treat the inflammation within the scope of the claims.

It is noted that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other "procedure" be used to assess cell activation. Accordingly (the Board concluded in their decision) that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the board's decision.

Here applicant argues the same as above, thus the rebuttal is the same as above. The level of activation of white blood cells is measured since inflammation is measured for the above reasons and since white blood cells are released when inflammation occurs, the level of activation of white blood cells will be inherently measured since the inflammation is also being measured for the above reasons.

Applicant has noted the same arguments as noted before, thus the rebuttal is the same as of record.

Claims 10, 11, 32 and 42 are rejected under 35 U.S.C. 102(e) as being anticipated by Rabkin et al.

Rabkin teaches that free radical production is measured using assays such as colormetric assays. Thus, when administering such compounds of Rabkin one can assess the damage of a disease/condition by assessing the free radical production as taught by Radkin (column 9, lines 40-50). Note also that Rabkin teaches that his invention could be administered to someone who has inflammatory disorders, see column 2, lines 40-60.

It is noted that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other "procedure" be used to assess cell activation. Accordingly (the Board concluded in their decision) that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the board's decision.

Applicant argues that the compounds of Rabkin are not administered before therapy for the disease or condition but as noted by the Board, the claims encompass a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the board's decision. Also note that the activation lowering therapy can be administered with the treatment for the disease or condition, see claim 10. Thus, this argument is without merit.

Applicant also argues that Rabkin does not meet the claims for the same reasons as Adams as discussed above, but the same rebuttal is offered for the same reasons as above for Adams.

Applicant has noted the same arguments as noted before, thus the rebuttal is the same as of record.

Claims 10, 11, 32 and 42 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 92/15707.

WO teaches that free radical production is assayed by using immunoassay methods, see abstract, page 20, line 15-page 21, line 10. WO uses its compositions to prevent inflammatory diseases, see abstract.

WO states that not only may this permit appropriate actions to avoid the pathogenic potential of these antibodies, but the detection serves in itself as a sensitive measure of ongoing oxidative damage. Thus, the detection of such antibodies may be used as the basis for modifying or terminating certain therapies or avoiding certain exposure risks (page 20, line 15- page 21, line 10).

It is noted that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other "procedure" be used to assess cell activation. Accordingly (the Board concluded in their decision)

that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the board's decision.

Applicant argues that WO does not meet the claims for the same reasons as Adams as discussed above, but the same rebuttal is offered for the same reasons as above for Adams.

Applicant has noted the same arguments as noted before, thus the rebuttal is the same as of record.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 10, 12-16, 18, 32, 34-36, 41 are rejected under 35 U.S.C. 103 as being obvious over Groutas in view of JP 409040579.

Groutas teaches that inflammation is associated with tissue trauma. Groutas also teaches that alpha-1-proteinase inhibitor is administered to reduce inflammation, see column 1, lines 1-45. Thus, as with the teachings of Adams as noted by the Board, the administration of alpha-1-proteinase will also treat the inflammation within the scope of the claims.

Groutas does not teach that futhan (nafamostat mesilate) is used as the specific protease inhibitor.

JP teaches that nafamostat mesilate is well known to be used to treat inflammation, specifically inflammatory bowel disease, see abstract. It establishes that one of ordinary skill in the art would have known at the time the invention was made that nafamostat mesilate (futhan) was known to treat inflammation.

Since JP clearly establishes that futhan was known at the time the invention was made to treat inflammation and since Groutas establishes that serine proteinase inhibitors such as alpha-1-proteinase inhibitor were known to treat inflammation then it would have been obvious to use futhan instead of alpha-1-proteinase since they both were known to treat inflammation at the time the invention was made and it clearly would have been within the purview of one of ordinary skill in the art to use either alpha-1-proteinase or futhan to treat inflammation. It is clear from JP '579 that the medicine (the fibrin paste containing the nafamostat mesilate-futhan) was capable of manifesting excellent effects on the suppression of relapse and keloplasty in the postoperative anastomosed part of the inflammatory bowel disease thus motivating one of ordinary

skill in the art to use the nafamostate mesilate instead of using of the alpha 1 proteinase since nafamostate mesilate was clearly known to achieve the above excellent effects.

It is noted that the Board very clearly delineated that in the appellant's specification or claims that there is no requirement that a blood test or other "procedure" be used to assess cell activation. Accordingly (the Board concluded in their decision) that the claims reads on a subject recognizing that the subject is experiencing inflammation, see pages 10-11 of the board's decision.

Thus, to use futhan (nafamostate mesilate) instead of alpha-1-proteinase as the protease inhibitor would have been *prima facie* obvious to one of ordinary skill in the art.

Applicant argues that JP and Groutas do not meet the claims for the same reasons as Adams as discussed above, but the same rebuttal is offered for the same reasons as above for Adams. Both Groutas and JP clearly are treating inflammation and for the above reasons and for the reasons of record it would have been obvious to administer futhan specifically for the above reasons.

Applicant has noted the same arguments as noted before, thus the rebuttal is the same as of record.

1. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 571-272-0967. The examiner can normally be reached on Monday thru Thursday: 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael V. Meller/

Primary Examiner, Art Unit 1655